In 2023, the mortality rate for prostate malignant neoplasms in the UK stood at 36.2 male deaths per hundred thousand men. The forecast from 2024 to 2028 shows a gradual decline in this mortality rate, dropping from 36.0 in 2024 to 35.6 in 2028. The year-on-year decrease remains stable at approximately 0.3%, suggesting a continuous albeit slow improvement in survival outcomes. Over the five-year period, the compound annual growth rate (CAGR) indicates an average annual decline of about 0.3% in the mortality rate.
Future trends to watch for include advancements in prostate cancer screening and treatment techniques, which might accelerate the decline in mortality rates. Additionally, innovations in personalized medicine and early detection technologies could further impact these trends substantially.
